The Latin America, Middle East and Africa Lysosomal Disease Treatment Market is expected to witness market growth of 12.7% CAGR during the forecast period (2022-2028).
The nervous system exhibits particularly high levels of ganglioside expression, and gangliosides are neurodegenerative disorders. Skeletal tissue expresses keratan and dermatan sulfate at high levels, and mucopolysaccharidoses, which have deficiencies in their breakdown mechanisms, are characterized by problem-related multiplex severe abnormalities in the development of skeletal cartilage and bone. Within each ailment, there is also a great deal of variety, from severe, infantile-onset types to attenuated adult-onset diseases, sometimes with different clinical symptoms. It is expected to make sense to say that this variance is a byproduct of the residual activity of the relevant metabolic pathway.
Since total enzyme deficiency is incompatible with extra-uterine life, it causes hydrops fetalis and the collodion infant phenotype, for instance, in Gaucher disease. Where there is little enzyme activity, storage happens quickly in several tissues, including neurons, leading to the quickly lethal juvenile neuronopathic phenotype (type 2 illness). For most tissues, even a little amount of residual activity can stop accumulation and stop neurodegeneration.
As lifestyle problems become more common, these relatively wealthy people is expected to continue to look for more expensive healthcare. The government has focused on creating a healthcare infrastructure to satisfy this need. In the United Arab Emirates, healthcare is governed by both the federal and provincial governments. The Health and Prevention Ministry is the most important government regulating organization for the healthcare sector in the UAE. To encourage foreign investment and raise the standard of healthcare in the country, the UAE government is easing regulations that boosts the growth of the lysosomal disease treatment market in this region.
The Brazil market dominated the LAMEA Lysosomal Disease Treatment Market by Country in 2021, thereby, achieving a market value of $235.1 Million by 2028. The Argentina market is obtained to grow at a CAGR of 13.3% during (2022 - 2028). Additionally, The UAE market is experiencing a CAGR of 12.4% during (2022 - 2028).
Based on Disease Type, the market is segmented into Gaucher's Diseases, Fabry Diseases, Mucopolysaccharidosis, Pompe’s Syndrome and Others. Based on Type of Therapy, the market is segmented into Enzyme Replacement Therapy, Substrate Reduction Therapy, Stem Cell Therapy and Others. Based on End User, the market is segmented into Hospitals, Clinics and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Merck & Co., Inc., Johnson & Johnson (Janssen Global Services, LLC), Eli Lilly And Company, Pfizer, Inc., Takeda Pharmaceutical Company Limited, Sanofi S.A., Novartis AG, AstraZeneca PLC (Alexion Pharmaceuticals, Inc.), BioMarin Pharmaceutical Inc. and Sigilon Therapeutics, Inc.
The nervous system exhibits particularly high levels of ganglioside expression, and gangliosides are neurodegenerative disorders. Skeletal tissue expresses keratan and dermatan sulfate at high levels, and mucopolysaccharidoses, which have deficiencies in their breakdown mechanisms, are characterized by problem-related multiplex severe abnormalities in the development of skeletal cartilage and bone. Within each ailment, there is also a great deal of variety, from severe, infantile-onset types to attenuated adult-onset diseases, sometimes with different clinical symptoms. It is expected to make sense to say that this variance is a byproduct of the residual activity of the relevant metabolic pathway.
Since total enzyme deficiency is incompatible with extra-uterine life, it causes hydrops fetalis and the collodion infant phenotype, for instance, in Gaucher disease. Where there is little enzyme activity, storage happens quickly in several tissues, including neurons, leading to the quickly lethal juvenile neuronopathic phenotype (type 2 illness). For most tissues, even a little amount of residual activity can stop accumulation and stop neurodegeneration.
As lifestyle problems become more common, these relatively wealthy people is expected to continue to look for more expensive healthcare. The government has focused on creating a healthcare infrastructure to satisfy this need. In the United Arab Emirates, healthcare is governed by both the federal and provincial governments. The Health and Prevention Ministry is the most important government regulating organization for the healthcare sector in the UAE. To encourage foreign investment and raise the standard of healthcare in the country, the UAE government is easing regulations that boosts the growth of the lysosomal disease treatment market in this region.
The Brazil market dominated the LAMEA Lysosomal Disease Treatment Market by Country in 2021, thereby, achieving a market value of $235.1 Million by 2028. The Argentina market is obtained to grow at a CAGR of 13.3% during (2022 - 2028). Additionally, The UAE market is experiencing a CAGR of 12.4% during (2022 - 2028).
Based on Disease Type, the market is segmented into Gaucher's Diseases, Fabry Diseases, Mucopolysaccharidosis, Pompe’s Syndrome and Others. Based on Type of Therapy, the market is segmented into Enzyme Replacement Therapy, Substrate Reduction Therapy, Stem Cell Therapy and Others. Based on End User, the market is segmented into Hospitals, Clinics and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Merck & Co., Inc., Johnson & Johnson (Janssen Global Services, LLC), Eli Lilly And Company, Pfizer, Inc., Takeda Pharmaceutical Company Limited, Sanofi S.A., Novartis AG, AstraZeneca PLC (Alexion Pharmaceuticals, Inc.), BioMarin Pharmaceutical Inc. and Sigilon Therapeutics, Inc.
Scope of the Study
Market Segments Covered in the Report:
By Disease Type- Gaucher's Diseases
- Fabry Diseases
- Mucopolysaccharidosis
- Pompe’s Syndrome
- Others
- Enzyme Replacement Therapy
- Substrate Reduction Therapy
- Stem Cell Therapy
- Others
- Hospitals
- Clinics
- Others
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Merck & Co., Inc.
- Johnson & Johnson (Janssen Global Services, LLC)
- Eli Lilly And Company
- Pfizer, Inc.
- Takeda Pharmaceutical Company Limited
- Sanofi S.A.
- Novartis AG
- AstraZeneca PLC (Alexion Pharmaceuticals, Inc.)
- BioMarin Pharmaceutical Inc.
- Sigilon Therapeutics, Inc.
Unique Offerings from the Publisher
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. LAMEA Lysosomal Disease Treatment Market by Disease Type
Chapter 4. LAMEA Lysosomal Disease Treatment Market by Type of Therapy
Chapter 5. LAMEA Lysosomal Disease Treatment Market by End User
Chapter 6. LAMEA Lysosomal Disease Treatment Market by Country
Chapter 7. Company Profiles
Companies Mentioned
- Merck & Co., Inc.
- Johnson & Johnson (Janssen Global Services, LLC)
- Eli Lilly And Company
- Pfizer, Inc.
- Takeda Pharmaceutical Company Limited
- Sanofi S.A.
- Novartis AG
- AstraZeneca PLC (Alexion Pharmaceuticals, Inc.)
- BioMarin Pharmaceutical Inc.
- Sigilon Therapeutics, Inc.
Methodology
LOADING...
